Humacyte, Inc. (NASDAQ:HUMAW) Sees Significant Decrease in Short Interest

Humacyte, Inc. (NASDAQ:HUMAW) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 2,478 shares, a drop of 42.0% from the December 31st total of 4,269 shares. Based on an average daily volume of 14,761 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 14,761 shares, the days-to-cover ratio is presently 0.2 days.

Humacyte Price Performance

Humacyte stock traded up $0.01 during trading hours on Friday, hitting $0.13. 23,800 shares of the stock were exchanged, compared to its average volume of 15,978. Humacyte has a 12 month low of $0.08 and a 12 month high of $1.69. The business’s 50-day moving average is $0.12 and its two-hundred day moving average is $0.23.

About Humacyte

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.